Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Moodys
Baxter
Colorcon
Merck

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,499,616

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,499,616
Title:Modulated lysine variant species compositions and methods for producing and using the same
Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimental, are also provided.
Inventor(s): Subramanian; Kartik (Northborough, MA), Thiele; Mayda Perez (Vega Alta, PR), Zeng; Xiaobei (Carolina, PR), Wong; Chee Furng (Singapore, SG), Kaymakcalan; Zehra (Westborough, MA), Jing; Ying (Wellesley, MA), Chumsae; Christopher M. (North Andover, MA)
Assignee: ABBVIE INC. (Chicago, IL)
Application Number:14/923,966
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,499,616
Patent Claims:1. A method for producing a composition comprising a human anti-TNF.alpha. antibody, comprising culturing a cell producing the antibody in a cell culture media comprising an amount of one or more basic amino acids sufficient to produce a composition comprising the antibody in which less than 65% of the lysine variant species of the antibody have zero C-terminal lysines (Lys 0), wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and wherein the antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4.

2. The method of claim 1, wherein the antibody is adalimumab.

3. The method of claim 2, wherein the one or more amino acids in the cell culture media is selected from the group consisting of arginine, lysine, histidine, ornithine, and combinations thereof.

4. The method of claim 3, wherein the one or more amino acids in the cell culture media is ornithine.

5. The method of claim 3, wherein the one or more amino acids in the cell culture media is arginine.

6. The method of claim 5, wherein the arginine concentration in the cell culture media is 6 to 9 g/L.

7. The method of claim 5, wherein the arginine concentration in the cell culture media is 6 g/L or more, 8 g/L or more, or 9 g/L or more.

8. The method of claim 3, wherein the one or more amino acids in the cell culture media is lysine.

9. The method of claim 8, wherein the lysine concentration in the cell culture media is 4 to 10 g/L.

10. The method of claim 8, wherein the lysine concentration in the cell culture media is 4 g/L or more, 8 g/L or more, or 10 g/L or more.

11. The method of claim 3, wherein the one or more amino acids in the cell culture media is histidine.

12. The method of claim 11, wherein the histidine concentration in the cell culture media is 8 g/L or more.

13. The method of claim 1, wherein 61% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

14. The method of claim 1, wherein 60% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

15. The method of claim 1, wherein 58% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

16. The method of claim 1, wherein 55% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

17. The method of claim 1, wherein 48% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

18. The method of claim 1, wherein the cell is a mammalian cell.

19. The method of claim 18, wherein the mammalian cell is selected from the group consisting of CHO cells, NS0 myeloma cells, COS cells, and SP2 cells.

20. A method for producing a composition comprising a human anti-TNF.alpha. antibody, comprising culturing a cell producing the antibody in a cell culture media comprising an amount of lysine sufficient to produce a composition comprising the antibody in which less than 65% of the lysine variant species of the antibody have zero C-terminal lysines (Lys 0), wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and wherein the human anti-TNF.alpha. antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4.

21. The method of claim 20, wherein the antibody is adalimumab.

22. The method of claim 21, wherein the lysine concentration in the cell culture media is 4 to 10 g/L.

23. The method of claim 21, wherein the lysine concentration in the cell culture media is 4 g/L or more.

24. The method of claim 21, wherein the lysine concentration in the cell culture media is 8 g/L or more.

25. The method of claim 21, wherein the lysine concentration in the cell culture media is 10 g/L or more.

26. The method of claim 21, wherein 61% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

27. The method of claim 21, wherein 55% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

28. The method of claim 21, wherein 48% or less of the lysine variant species of said antibody have zero C-terminal lysines (Lys 0).

29. The method of claim 21, wherein the cell is a mammalian cell.

30. The method of claim 29, wherein the mammalian cell is selected from the group consisting of CHO cells, NS0 myeloma cells, COS cells, and SP2 cells.

Details for Patent 9,499,616

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 2002-12-31 ⤷  Try it Free 2033-10-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 2008-02-21 ⤷  Try it Free 2033-10-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 2013-04-24 ⤷  Try it Free 2033-10-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 2014-09-23 ⤷  Try it Free 2033-10-18
Abbvie Inc. HUMIRA adalimumab Injection 125057 2015-11-23 ⤷  Try it Free 2033-10-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Boehringer Ingelheim
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.